{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:59:20Z","timestamp":1788944360653,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.actbio.2025.03.023","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T19:32:24Z","timestamp":1742067144000},"page":"374-385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Immuno-engineered macrophage membrane-coated nanodrug to restore immune balance for rheumatoid arthritis treatment"],"prefix":"10.1016","volume":"197","author":[{"given":"Xiaofang","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinsheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.actbio.2025.03.023_bib0001","first-page":"591","article-title":"Global epidemiology of rheumatoid arthritis","volume":"18","author":"Finckh","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"issue":"12","key":"10.1016\/j.actbio.2025.03.023_bib0002","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.immuni.2022.11.009","article-title":"The pathogenesis of rheumatoid arthritis","volume":"55","author":"Alivernini","year":"2022","journal-title":"Immunity."},{"issue":"1","key":"10.1016\/j.actbio.2025.03.023_bib0003","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaci.2022.11.001","article-title":"Immune dysregulation","volume":"151","author":"Long","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"issue":"7","key":"10.1016\/j.actbio.2025.03.023_bib0004","doi-asserted-by":"crossref","first-page":"10018","DOI":"10.1002\/jcp.27860","article-title":"Strategies toward rheumatoid arthritis therapy; the old and the new","volume":"234","author":"Abbasi","year":"2019","journal-title":"J. Cell Physiol."},{"issue":"16","key":"10.1016\/j.actbio.2025.03.023_bib0005","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of Upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.actbio.2025.03.023_bib0006","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41584-021-00593-3","article-title":"Cardiovascular effects of approved drugs for rheumatoid arthritis","volume":"17","author":"Atzeni","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.actbio.2025.03.023_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002012","article-title":"Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study","volume":"8","author":"Fleischmann","year":"2022","journal-title":"RMD. Open."},{"issue":"1","key":"10.1016\/j.actbio.2025.03.023_bib0008","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41590-020-00816-x","article-title":"The immunology of rheumatoid arthritis","volume":"22","author":"Weyand","year":"2021","journal-title":"Nat. Immunol."},{"issue":"28","key":"10.1016\/j.actbio.2025.03.023_bib0009","doi-asserted-by":"crossref","first-page":"11270","DOI":"10.1073\/pnas.1120611109","article-title":"Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis","volume":"109","author":"Yeste","year":"2012","journal-title":"Proc. Natl. Acad. Sci. u S. a"},{"key":"10.1016\/j.actbio.2025.03.023_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.657768","article-title":"Emerging therapeutics for Immune tolerance: tolerogenic vaccines, T cell therapy, and IL-2 therapy","volume":"12","author":"Moorman","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2025.03.023_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102392","article-title":"An overview of autoantibodies in rheumatoid arthritis","volume":"110","author":"van Delft","year":"2020","journal-title":"J. Autoimmun."},{"issue":"20","key":"10.1016\/j.actbio.2025.03.023_bib0012","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160964","article-title":"Randomized phase I trial of antigen-specific tolerizing immunotherapy with peptide\/calcitriol liposomes in ACPA+ rheumatoid arthritis","volume":"7","author":"Sonigra","year":"2022","journal-title":"JCI. Insight."},{"issue":"16","key":"10.1016\/j.actbio.2025.03.023_bib0013","first-page":"20119","article-title":"Autoantigenic peptide and immunomodulator codelivery system for rheumatoid arthritis treatment by reestablishing immune tolerance","volume":"16","author":"Mai","year":"2024","journal-title":"ACS. Appl. Mater. Interfaces."},{"issue":"11","key":"10.1016\/j.actbio.2025.03.023_bib0014","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.autrev.2014.08.012","article-title":"Anti-citrullinated peptides as autoantigens in rheumatoid arthritis-relevance to treatment","volume":"13","author":"Sakkas","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.actbio.2025.03.023_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113928","article-title":"Advancedoral vaccine delivery strategies for improving the immunity","volume":"177","author":"Zhang","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2025.03.023_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102643","article-title":"The role and mechanism of triptolide, a potential new DMARD, in the treatment of rheumatoid arthritis","volume":"104","author":"Wang","year":"2025","journal-title":"Ageing Res. Rev."},{"issue":"3","key":"10.1016\/j.actbio.2025.03.023_bib0017","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/med.21762","article-title":"Tripterygium wilfordii: an inspiring resource for rheumatoid arthritis treatment","volume":"41","author":"Zhang","year":"2021","journal-title":"Med. Res. Rev."},{"issue":"2","key":"10.1016\/j.actbio.2025.03.023_bib0018","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1745-7254.2005.00035.x","article-title":"Triptolide suppresses CD80 and CD86 expressions and IL-12 production in THP-1 cells","volume":"26","author":"Liu","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"issue":"13","key":"10.1016\/j.actbio.2025.03.023_bib0019","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of Upadacitinib and Adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2025.03.023_bib0020","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ejmech.2018.12.058","article-title":"Triptolide-targeted delivery methods","volume":"164","author":"Xu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.actbio.2025.03.023_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2023.110651","article-title":"Recent advances in the pharmacological applications and liver toxicity of triptolide","volume":"382","author":"Cui","year":"2023","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.actbio.2025.03.023_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105377","article-title":"Triptolide delivery: nanotechnology-based carrier systems to enhance efficacy and limit toxicity","volume":"165","author":"Ren","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.actbio.2025.03.023_bib0023","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnology."},{"issue":"23","key":"10.1016\/j.actbio.2025.03.023_bib0024","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201706759","article-title":"Cell membrane coating nanotechnology","volume":"30","author":"Fang","year":"2018","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.actbio.2025.03.023_bib0025","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1038\/s41467-020-16439-7","article-title":"Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines","volume":"11","author":"Gao","year":"2020","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.actbio.2025.03.023_bib0026","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202200289","article-title":"Macrophage Cell Membrane-Cloaked Nanoplatforms for Biomedical Applications","volume":"6","author":"Lopes","year":"2022","journal-title":"Small Methods"},{"issue":"5","key":"10.1016\/j.actbio.2025.03.023_bib0027","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41577-023-00970-x","article-title":"Therapeutic induction of antigen-specific immune tolerance","volume":"24","author":"Kenison","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.actbio.2025.03.023_bib0028","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41590-020-0620-x","article-title":"PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer","volume":"21","author":"Diskin","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.actbio.2025.03.023_bib0029","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s13075-015-0859-z","article-title":"Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways","volume":"17","author":"Liu","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.actbio.2025.03.023_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202105530","article-title":"Nanovaccines mediated subcutis-to-intestine cascade for improved protection against intestinal infections","volume":"18","author":"Zhong","year":"2022","journal-title":"Small."},{"issue":"3","key":"10.1016\/j.actbio.2025.03.023_bib0031","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/10408398.2014.893503","article-title":"Effects of composition and processing variables on the oxidative stability of protein-based and oil-in-water food emulsions","volume":"57","author":"Kiokias","year":"2017","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.actbio.2025.03.023_bib0032","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.actbio.2020.11.027","article-title":"Construction of a pH-responsive, ultralow-dose triptolide nanomedicine for safe rheumatoid arthritis therapy","volume":"121","author":"Liu","year":"2021","journal-title":"Acta Biomater."},{"issue":"5","key":"10.1016\/j.actbio.2025.03.023_bib0033","article-title":"Immune Checkpoint Ligand bioengineered Schwann cells as antigen-specific therapy for experimental autoimmune encephalomyelitis","volume":"34","author":"Au","year":"2022","journal-title":"Adv. Mater."},{"issue":"12","key":"10.1016\/j.actbio.2025.03.023_bib0034","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202108817","article-title":"Immuno-engineered nanodecoys for the multi-target anti-inflammatory treatment of autoimmune diseases","volume":"34","author":"Hou","year":"2022","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.actbio.2025.03.023_bib0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20010204","article-title":"Exploiting PLGA-based biocompatible nanoparticles for next-generation tolerogenic vaccines against autoimmune disease","volume":"20","author":"Cappellano","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.actbio.2025.03.023_bib0036","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s11658-020-00214-z","article-title":"The role of phosphatidylserine recognition receptors in multiple biological functions","volume":"25","author":"Naeini","year":"2020","journal-title":"Cell Mol. Biol. Lett."},{"key":"10.1016\/j.actbio.2025.03.023_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.102994","article-title":"C-terminal citrullinated peptide alters antigen-specific APC:t cell interactions leading to breach of immune tolerance","volume":"135","author":"Malcolm","year":"2023","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.actbio.2025.03.023_bib0038","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12951-020-00675-6","article-title":"Exosome-based biomimetic nanoparticles targeted to inflamed joints for enhanced treatment of rheumatoid arthritis","volume":"18","author":"Yan","year":"2020","journal-title":"J. Nanobiotechnology."},{"issue":"11","key":"10.1016\/j.actbio.2025.03.023_bib0039","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1136\/ard.2007.076430","article-title":"Utility of animal models for identification of potential therapeutics for rheumatoid arthritis","volume":"67","author":"Hegen","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.actbio.2025.03.023_bib0040","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/ard-2023-224479","article-title":"New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A\/F function","volume":"82","author":"Saviano","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.actbio.2025.03.023_bib0041","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41584-018-0109-2","article-title":"Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis","volume":"15","author":"Chen","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"issue":"5","key":"10.1016\/j.actbio.2025.03.023_bib0042","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nprot.2007.173","article-title":"Collagen-induced arthritis","volume":"2","author":"Brand","year":"2007","journal-title":"Nat. Protoc."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706125001977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706125001977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:31:32Z","timestamp":1777793492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706125001977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":42,"alternative-id":["S1742706125001977"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2025.03.023","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immuno-engineered macrophage membrane-coated nanodrug to restore immune balance for rheumatoid arthritis treatment","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2025.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Acta Materialia Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}